全文获取类型
收费全文 | 411篇 |
免费 | 193篇 |
国内免费 | 8篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 1篇 |
基础医学 | 20篇 |
口腔科学 | 3篇 |
临床医学 | 26篇 |
内科学 | 25篇 |
皮肤病学 | 16篇 |
神经病学 | 20篇 |
特种医学 | 2篇 |
外科学 | 342篇 |
综合类 | 32篇 |
预防医学 | 2篇 |
眼科学 | 9篇 |
药学 | 83篇 |
中国医学 | 8篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 12篇 |
2022年 | 11篇 |
2021年 | 49篇 |
2020年 | 56篇 |
2019年 | 48篇 |
2018年 | 45篇 |
2017年 | 61篇 |
2016年 | 50篇 |
2015年 | 48篇 |
2014年 | 22篇 |
2013年 | 33篇 |
2012年 | 12篇 |
2011年 | 16篇 |
2010年 | 17篇 |
2009年 | 16篇 |
2008年 | 14篇 |
2007年 | 12篇 |
2006年 | 7篇 |
2005年 | 17篇 |
2004年 | 14篇 |
2003年 | 9篇 |
2002年 | 9篇 |
2001年 | 8篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1998年 | 5篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1988年 | 1篇 |
排序方式: 共有612条查询结果,搜索用时 31 毫秒
1.
2.
Hideo Kanauchi Sadao Imamura Masahiro Takigawa Fukumi Furukawa 《The Journal of dermatology》1994,21(12):935-939
Kampo, a Japanese-Chinese traditional herbal medicine, has been used for the treatment of various diseases for about 3,000 years in China. Among herbal medicines, Sairei-to is well known for improving the symptoms of rheumatoid arthritis (RA) and other collagen diseases. However, its immunosuppressive effects on autoimmune cutaneous phenomena are not completely understood. We investigated the effects of Sairei-to on the development of lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr (MRL/lpr) mice, an animal model which spontaneously develops skin lesions similar to those seen in human lupus erythematosus. Virgin female MRL/lpr mice at 1 month of age, which were treated orally with Sairei-to, had reduced amounts of IgG deposition at the dermoepidermal junction, titers of anti-DNA antibodies and rheumatoid factor, and lymphoproliferation. These results support the use of traditional herbal medicines in patients with human RA and systemic lupus erythematosus. 相似文献
3.
异体造血干细胞移植的重要并发症是移植物抗宿主病(GVHD),免疫抑制剂是有效防治GVHD的一类药物.在异体造血干细胞移植后应用免疫抑制剂,使得GVHD发生率下降,严重程度减轻.本文对几类主要的免疫抑制剂的作用机理以及在异体造血干细胞移植中作为预防和治疗GVHD的应用作一综述. 相似文献
4.
C Morland J Michael D Adu T Kizaki A J Howie A Morgan N A Staines 《Clinical and experimental immunology》1991,83(1):126-132
The effect of the administration of a xenogeneic anti-idiotype antibody (anti-Id33) to a cross-reactive idiotype (Id33) present on anti-dsDNA antibody was examined in 6-week-old (NZB/NZW) F1 (BWF1) female mice. The administration of anti-Id33 led to a transient reduction in immunoglobulins expressing Id33, followed by a rise at 30 and 34 weeks that was significantly higher than in untreated mice (P less than 0.05). Likewise, anti-dsDNA antibody levels were significantly higher at 10 and 18 weeks than in untreated mice (P less than 0.01). No differences were seen in survival to 40 weeks, proteinuria or the severity of glomerulonephritis. Concurrent administration of cyclosporin A (CyA) with anti-Id33 markedly ameliorated glomerular injury and proteinuria and improved survival. By contrast, glomerular injury, proteinuria and survival were worse in mice treated with cyclophosphamide plus anti-Id33, compared with untreated mice. Neither CyA nor cyclophosphamide treatment, when given with anti-Id33 altered serum levels of anti-dsDNA, anti-ssDNA or Id33+ immunoglobin, compared with untreated mice. The different effects of CyA and cyclophosphamide on T lymphocytes and their discrepant effects on glomerular injury when given with anti-Id33 in this model lead us to postulate a role for T lymphocytes in the glomerular injury of BWF1 lupus. 相似文献
5.
肾移植受者T淋巴细胞核仁区酸性非组蛋白表达活性研究 总被引:2,自引:2,他引:0
目的探讨T淋巴细胞核仁区酸性非组蛋白表达活性(Ag-NORs)对肾移植受者术前及术后用药病情监测的应用价值.方法应用普通细胞银染技术对32例肾移植患者术前及术后使用免疫抑制剂1,2,3周外周血T淋巴细胞染色,通过计算机显微图像分析技术,计算硝酸银染色酸性非组蛋白(Ag-NORs)面积与核面积的比值(I*S%).结果肾移植患者术前Ag-NORs的I*S%为(6.31±0.86);术后使用免疫抑制剂1,2,3周Ag-NORs的I*S%分别为(4.72±0.93),(4.28±1.05),(4.66±1.21).肾移植术后各期与术前Ag-NORs的I*S%差异有显著性意义(P<0.01);术后各期之间Ag-NORs的I*S%差异无显著性意义(P>0.05).结论T淋巴细胞核仁酸性非组蛋白表达活性在肾移植及其术后用药病情监测中具有重要的意义. 相似文献
6.
7.
William A. Werbel Sunjae Bae Sile Yu Fawaz Al Ammary Dorry L. Segev Christine M. Durand 《American journal of transplantation》2021,21(2):717-726
Kidney transplant (KT) outcomes for HIV-infected (HIV+) persons are excellent, yet acute rejection (AR) is common and optimal immunosuppressive regimens remain unclear. Early steroid withdrawal (ESW) is associated with AR in other populations, but its utilization and impact are unknown in HIV+ KT. Using SRTR, we identified 1225 HIV+ KT recipients between January 1, 2000, and December 31, 2017, without AR, graft failure, or mortality during KT admission, and compared those with ESW with those with steroid continuation (SC). We quantified associations between ESW and AR using multivariable logistic regression and interval-censored survival analysis, as well as with graft failure and mortality using Cox regression, adjusting for donor, recipient, and immunologic factors. ESW utilization was 20.4%, with more zero HLA mismatch (8% vs 4%), living donors (26% vs 20%), and lymphodepleting induction (64% vs 46%) compared to the SC group. ESW utilization varied widely across 129 centers, with less use at high- versus moderate-volume centers (6% vs 21%, P < .001). AR was more common with ESW by 1 year (18.4% vs 12.3%; aOR: 1.081.612.41, P = .04) and over the study period (aHR: 1.021.391.90, P = .03), without difference in death-censored graft failure (aHR 0.600.911.36, P = .33) or mortality (aHR: 0.751.151.77, P = .45). To reduce AR after HIV+ KT, tailoring of ESW utilization is reasonable. 相似文献
8.
Burkhard Tönshoff Helio Tedesco-Silva Robert Ettenger Martin Christian Anna Bjerre Luca Dello Strologo Stephen D. Marks Lars Pape Udaykiran Veldandi Patricia Lopez Marc Cousin Priti Pandey Matthias Meier 《American journal of transplantation》2021,21(1):123-137
CRADLE was a 36-month multicenter study in pediatric (≥1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54) with corticosteroids. The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at month 36 was 9.8% vs 9.6% (difference: 0.2%; 80% confidence interval: −7.3 to 7.7) for EVR + rTAC and MMF + sTAC, respectively, which was driven by BPARs. Graft loss was low (2.1% vs 3.8%) with no deaths. Mean estimated glomerular filtration rate at month 36 was comparable between groups (68.1 vs 67.3 mL/min/1.73 m2). Mean changes (z-score) in height (0.72 vs 0.39; P = .158) and weight (0.61 vs 0.82; P = .453) from randomization to month 36 were comparable, whereas growth in prepubertal patients on EVR + rTAC was better (P = .050) vs MMF + sTAC. The overall incidence of adverse events (AEs) and serious AEs was comparable between groups. Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group. In conclusion, though AE-related study drug discontinuation was higher, an EVR + rTAC regimen represents an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for pediatric kidney transplant recipients. ClinicalTrials.gov: NCT01544491. 相似文献
9.
Rabea Asleh Hilmi Alnsasra Amir Lerman Alexandros Briasoulis Naveen L. Pereira Brooks S. Edwards Takumi Toya John M. Stulak Alfredo L. Clavell Richard C. Daly Sudhir S. Kushwaha 《American journal of transplantation》2021,21(2):626-635
We have previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. We sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied. CAV progression was assessed by measuring the Δ change in plaque volume (PV) and plaque index (PI) per year using coronary intravascular ultrasound. Proteinuria was defined as Δ urine protein ≥300 mg/24 h at 1 year after conversion to SRL. Overall, 137 patients were analyzed (26% with proteinuria). Patients with proteinuria had significantly lower GFR (P = .005) but similar GFR during follow-up. Delta PV (P < .001) and Δ PI (P = .001) were significantly higher among patients with proteinuria after adjustment for baseline characteristics. Multivariate Cox regression analysis showed higher all-cause mortality (hazard ratio 3.8; P = .01) with proteinuria but similar risk of CAV-related events (P = .61). Our results indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk. 相似文献
10.